Abstract
The N-methyl-D-aspartate receptor (NMDAR), a subtype of ionotropic glutamate receptor, has been implicated in a host of chronic and acute neurological disorders. Accordingly, much emphasis has been placed on the development of safe and effective therapeutic agents that specifically antagonize this target. The conantokins are a class of small, naturally occurring peptides that inhibit ion flow through the NMDAR. Some conantokins demonstrate receptor subunit selectivity, a pharmacological attribute of emerging importance in the search for suitable drug candidates. The current review summarizes the NMDAR inhibitory properties of the conantokins, including structure-function relationships and mechanism of action. This information is fundamental to the rational design of suitable agents that can effectively treat pathophysiologies linked to NMDAR dysfunction.
Keywords: ionotropic glutamate receptors, NR1 exons, long-term potentiation, Conantokin Inhibition, NMDAR antagonists
Current Drug Targets
Title: The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Volume: 8 Issue: 5
Author(s): Mary Prorok and Francis J. Castellino
Affiliation:
Keywords: ionotropic glutamate receptors, NR1 exons, long-term potentiation, Conantokin Inhibition, NMDAR antagonists
Abstract: The N-methyl-D-aspartate receptor (NMDAR), a subtype of ionotropic glutamate receptor, has been implicated in a host of chronic and acute neurological disorders. Accordingly, much emphasis has been placed on the development of safe and effective therapeutic agents that specifically antagonize this target. The conantokins are a class of small, naturally occurring peptides that inhibit ion flow through the NMDAR. Some conantokins demonstrate receptor subunit selectivity, a pharmacological attribute of emerging importance in the search for suitable drug candidates. The current review summarizes the NMDAR inhibitory properties of the conantokins, including structure-function relationships and mechanism of action. This information is fundamental to the rational design of suitable agents that can effectively treat pathophysiologies linked to NMDAR dysfunction.
Export Options
About this article
Cite this article as:
Prorok Mary and Castellino J. Francis, The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function, Current Drug Targets 2007; 8 (5) . https://dx.doi.org/10.2174/138945007780618481
DOI https://dx.doi.org/10.2174/138945007780618481 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Psychopharmacologic Treatment of Children and Adolescents with Bipolar Disorder: A Review
Adolescent Psychiatry ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Modulation of GABAA Receptors in the Treatment of Epilepsy
Current Pharmaceutical Design Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Meldrum's Acid in Organic Synthesis, an Outlook to Reaction Media
Current Organic Chemistry Role of Quercetin in the Mitigation of Lindane Induced Toxicity in Terms of Oxidative Responses and Metabolic Status in Mice Brain
Current Bioactive Compounds The Orexin System: A Potential Player in the Pathophysiology of Absence Epilepsy
Current Neuropharmacology ORO-Dental Manifestations in West Syndrome
Current Topics in Medicinal Chemistry Activity of Drugs and Components of Natural Origin in the Severe Myoclonic Epilepsy of Infancy (Dravet Syndrome)
Central Nervous System Agents in Medicinal Chemistry Neurosteroids and Sporadic Alzheimers Disease
Current Alzheimer Research Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Opioid Receptor Ligands Derived from Food Proteins
Current Pharmaceutical Design Role of Cation-Chloride-Cotransporters (CCC) in Pain and Hyperalgesia
Current Topics in Medicinal Chemistry N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence
CNS & Neurological Disorders - Drug Targets Recent Advances in the Hofmann Rearrangement and Its Application to Natural Product Synthesis
Current Organic Chemistry Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies
Medicinal Chemistry The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies
Current Neuropharmacology Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Current Organic Synthesis